Arena Pharmaceuticals

Clinical-stage biotech focused on cardiovascular, central nervous system, inflammatory and metabolic diseases. Their leading drug candidate is lorcaserin hydrochloride, which recently received positive data from a clinical trial. They are headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

At a stroke, the pharmaceutical company has become nearly $7 billion larger with a new asset.

Why Pfizer Stock Jumped While the Market Stumbled Today

Shares of Pfizer Inc. PFE, +2.32% were up 2.0% in trading on Friday after the company said it closed its $6.7 billion acquisition of Arena Pharmaceuticals Inc. Arena is developing treatments for immuno-inflammatory diseases like ulcerative colitis and atopic dermatitis. It has said it expects to share data from a Phase 3 clinical trial testing one of those experimental therapies, etrasimod, in ulcerative colitis patients during the first quarter of his year.

Pfizer closes $6.7 billion acquisition of Arena Pharmaceuticals

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Arena Pharmaceuticals brings to Pfizer a portfolio of diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor

Pfizer Completes Acquisition of Arena Pharmaceuticals

Akebia Therapeutics

Amylyx Pharmaceuticals

Ascendis Pharma

Bristol-Myers

IMARA

Terns Pharmaceuticals

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on InvestorPlace.

7 Biotech Stocks With Key Catalysts in March

Clever Leaves Holdings Inc

Flora Growth Corp

HEXO Corp

High Tide

FSD Pharma

Innovative Industrial Properties

Tilray Brands

22nd Century Group

cbdMD Inc

WM Technology

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we make our way through 2022.

11 Marijuana Stocks on Fire to Close February

Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.

Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021

Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates

GrowGeneration Corp

Village Farms International

The marijuana industry has seen sharp growth year on year.

Top 3 weed stocks to put on your watch list this year

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commencement date of February 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement RSUs vest over four y

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets. About Arena Pharmaceuticals ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients. In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our s

Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23

NEW ORLEANS, Jan. 4, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Arena Pharmaceuticals INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arena Pharmaceuticals, Inc. - ARNA

Pfizer Inc.'s presentation of its pending $6.7 billion acquisition of clinical-stage drug company Arena Pharmaceuticals Inc. contained no mention of cannabis.

Cannabis Watch: Pfizer's Arena Pharma deal may lead drug company to a cannabis-based treatment

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Should You Buy Arena Pharmaceuticals, Inc. (ARNA) After Golden Cross?

Arena Pharmaceuticals got acquired by Pfizer for US$ 6.7 Bn (~100% valuation) on December 12th. As a result, the market for late-stage oral IBD candidates that big pharma can acquire is thinning.

Abivax: Potentially The Next Arena Pharmaceuticals, Most Ideal Big Pharma M&A Target In 2022

Pfizer (PFE) signs an agreement to acquire Arena Pharmaceuticals for $6.7 billion in cash. Stock rises.

Pfizer (PFE) to Buy Arena, Boost Immuno-Inflammatory Pipeline

The Pfizer (PFE)-Arena (ARNA) deal raises hopes that M&A activity will pick up significantly in 2022. as big drugmakers are sitting on huge piles of cash.

Does PFE, ARNA Deal Signal Robust Pharma M&A Activity in 2022?

Pfizer Inc's (NYSE:PFE) agreed acquisition of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) for almost double the closing price of the stock in the previous trading sessions, is just the latest case of big pharma's confidence to get into cannabinoid-based research, said the manager of an ETF focused on the sector. Nawan Butt, portfolio manager of The Medical Cannabis and Wellness UCITS ETC (CBDX) says it is also another example of the huge growth potential for the medical cannabis sector and how it is becoming more mainstream.

Pfizer's acquisition of Arena "shows big pharma's interest in cannabinoid medicines"

A healthcare titan wants to acquire the drug developer for nearly $7 billion.

Why Arena Pharmaceuticals Stock Skyrocketed 80% Today

MILWAUKEE, Dec. 13, 2021 /PRNewswire/ -- Ademi LLP is investigating Arena (Nasdaq: ARNA), for possible breaches of fiduciary duty and other violations of law in its transaction Pfizer.  Click here to learn how to join the action: https://www.ademilaw.com/case/arena-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Arena Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Pfizer Inc.

NEW YORK, Dec. 13, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Arena Pharmaceuticals, Inc. ("Arena" or the "Company") (NASDAQ: ARNA), in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (NYSE: PFE).  Under the terms of the merger agreement, the Company's shareholders will receive $100.00 per share in cash for each share of Arena common stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Arena Pharmaceuticals, Inc.

Pfizer Inc (NYSE: PFE) executed a definitive agreement with Arena Pharmaceuticals (Nasdaq: ARNA), under which Pfizer Inc will acquire Arena Pharmaceutical for a total equity value of around $6.7 billion. Arena went up 90% after this announcement.

Arena Pharmaceuticals up 90% after acquisition announcement

Pfizer Inc. said Monday it has agreed to acquire Arena Pharmaceuticals Inc. in a deal with a value of about $6.7 billion, sending both stocks sharply higher.

Pfizer stock heads toward record after $6.7 billion takeover of Arena; deal ‘makes strategic sense to us,' says analyst

Arena Pharmaceuticals (ARNA) stock is flying higher on Monday thanks to a huge $6.7 billion acquisition deal with Pfizer (PFE). The post ARNA Stock Alert: The Pfizer Deal That Has Arena Pharmaceuticals Rocketing Today appeared first on InvestorPlace.

ARNA Stock Alert: The Pfizer Deal That Has Arena Pharmaceuticals Rocketing Today

Pharmaceutical giant Pfizer Inc. (NYSE:PFE) is entering the cannabis space via the $6.7 billion acquisition of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). The two publicly-traded companies confirmed Monday that they have signed a definitive agreement under which Pfizer will acquire all outstanding shares of Arena for $100 per share in an all-cash transaction.

How Pfizer Is Getting Into Cannabis With $6.7B Arena Pharma Deal

Arena Pharmaceuticals Inc (NASDAQ: ARNA) is soaring Monday morning after Pfizer Inc (NYSE: PFE) announced it would acquire the company for $100 per share. The all-cash transaction represents a total equity value of approximately $6.7 billion.

News for Arena Pharmaceuticals Stock (ARNA)